| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H12N2O4 |
| Molecular Weight | 248.2347 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN([C@@H]2O[C@](CO)(C=C2)C#C)C(=O)NC1=O
InChI
InChIKey=OSYWBJSVKUFFSU-SKDRFNHKSA-N
InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1
| Molecular Formula | C12H12N2O4 |
| Molecular Weight | 248.2347 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Censavudine (also known as BMS-986001) is thymidine analogue and nucleosidereverse transcriptase inhibitors developed by Bristol Myers-Squibb for the treatment of HIV infection. In single-cycle assays, Censavudine inhibited HIV-2 isolates from treatment-naive individuals, with 50% effective concentrations (EC50s) ranging from 30 to 81 nM. Censavudine is the first nucleoside analog that, when tested against a diverse collection of HIV-1 and HIV-2 isolates, exhibits more potent activity against HIV-2 than against HIV-1 in culture. In clinical trials Censavudine was generally well tolerated through week 48 and similar efficacy to that of tenofovir disoproxil fumarate
Originator
Approval Year
|
|
TARGET ORGANISM->INHIBITOR |
|
Showing 1 to 1 of 1 entries
